Uric acid nephrolithiasis: A systemic metabolic disorder

Clinical Reviews in Bone and Mineral Metabolism

Volumn 9, Issue 3-4, 2011, Pages 207-217

  Wiederkehr, Michael R ^a   Moe, Orson W ^b,c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Acid urine; Alkaline; Ammonium; Gout; Hyperuricosuria; Metabolic syndrome; PH; Potassium citrate; Uric acid nephrolithiasis; Urine buffer

Indexed keywords

ACETAZOLAMIDE; ALLOPURINOL; BICARBONATE; BUFFER; CITRATE POTASSIUM; CITRATE SODIUM; FEBUXOSTAT; HYPOXANTHINE; POTASSIUM BICARBONATE; TOPIRAMATE; URIC ACID; XANTHINE; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR;

ACIDURIA; ARTICLE; CHRONIC DIARRHEA; COMPUTER ASSISTED TOMOGRAPHY; FLUID INTAKE; GASTROINTESTINAL DISEASE; GOUT; HUMAN; HYPERURICOSURIA; METABOLIC ACIDOSIS; METABOLIC DISORDER; NEPHROLITHIASIS; PATHOPHYSIOLOGY; PREVALENCE; STONE FORMATION; SYSTEMIC DISEASE; ULTRASOUND; URIC ACID BLOOD LEVEL; URIC ACID STONE; URINE PH; URINE VOLUME;

EID: 84855899409     PISSN: 15348644     EISSN: 15590119     Source Type: Journal    
DOI: 10.1007/s12018-011-9106-6     Document Type: Article

References (79)

1. Balinsky JB. Phylogenetic aspects of purine metabolism. S Afr Med J. 1972;46(29):993-7.
2. Campbell JW, Comparative biochemistry of nitrogen metabolism. In: Campbell JW, editor. The vertebrates, Vol. 2. New York: Academic Press; 1970.
3. Moe OW. Uric acid nephrolithiasis: proton titration of an essential molecule? Curr Opin Nephrol Hypertens. 2006;15(4): 366-73. (Pubitemid 44297978)
4. Shoemaker VH, et al. Uricotelism and low evaporative water loss in a South American frog. Science. 1972;175(25):1018-20.
5. Christen P, et al. Urate oxidase in primates. Folia Primatol (Basel). 1970;13(1):35-9.
6. Varela-Echavarria A, Montes de Oca-Luna R, Barrera-Saldana HA. Uricase protein sequences: conserved during vertebrate evolution but absent in humans. FASEB J. 1988;2(15):3092-6.
7. Shattock SG. Prehistoric or predynastic Egyptian calculus. Trans Path Sci Lond. 1905;56-62.
8. Moran ME. Uric acid stone disease. Front Biosci. 2003;8: s1339-55. (Pubitemid 38925392)
9. Sydenham T. Tractatus de podagra et hydrope. London: Walter Kettibly; 1683.
10. Scheele C. Examen Chemicum Calculi Urinari. Opuscula. 1776; 2:73.
11. Coley NG. Medical chemists and the origins of clinical chemistry in Britain (circa 1750-1850). Clin Chem. 2004;50(5):961-72. (Pubitemid 38543684)
12. Wollaston WH. On gouty and urinary concretions. Philos Trans R Soc Lond. 1797;87:386-400.
13. Wollaston WH. On cystic oxide, a new species of urinary calculus. Philos Trans R Soc Lond. 1810;100:223-30.
14. Pearson G. Experiments and observations, tending to show the composition and properties of urinary concretions. Philos Trans R Soc Lond. 1798;88:15-46.
15. Smeaton WA (1963) Fourcroy, chemist and revolutionary (1755-1809). 7(3):287.
16. Ellis H. A history of bladder stone. J Royal Soc Med. 1979; 72(4):248-51. (Pubitemid 9142200)
17. Osler W. The principles and practice of medicine: designed for the use of practitioners and students of medicine. Young J Pentland: Edinburgh & London; 1892. pp. 765-770.
18. Gutman AB, Yu TF. Uric acid nephrolithiasis. Am J Med. 1968; 45(5):756-79.
19. Mandel NS, Mandel GS. Urinary tract stone disease in the United States veteran population. II. Geographical analysis of variations in composition. J Urol. 1989; 142(6):1516-21. (Pubitemid 20011971)
20. Gault MH, Chafe L. Relationship of frequency, age, sex, stone weight, composition in 15, 624 stones: comparison of resutls for 1980 to 1983, 1995 to 1998. J Urol. 2000;164(2):302-7. (Pubitemid 30481910)
21. Knoll T, et al. Urolithiasis through the ages: data on more than 200, 000 urinary stone analyses. J Urol. 2011;185(4):1304-11.
22. Gentle DL, et al. Geriatric urolithiasis. J Urol. 1997;158(6): 2221-4. (Pubitemid 27481361)
23. Henneman PH, Wallach S, Dempsey EF. The metabolism defect responsible for uric acid stone formation. J Clin Invest. 1962; 41:537-42.
24. Zaidman JL, Pinto N. Studies on urolithiasis in Israel. J Urol. 1976;115(6):626-7.
25. Portis AJ, et al. Stone disease in the Hmong of Minnesota: initial description of a high-risk population. J Endourol. 2004;18(9): 853-7. (Pubitemid 39627563)
26. Ansari MS, et al. Spectrum of stone composition: structural analysis of 1050 upper urinary tract calculi from northern India. Int J Urol. 2005;12(1):12-6. (Pubitemid 40332997)
27. Hossain RZ, et al. Urolithiasis in Okinawa, Japan: a relatively high prevalence of uric acid stones. Int J Urol. 2003;10(8):411-5. (Pubitemid 37040994)
28. Pak CY, et al. Biochemical profile of stone-forming patients with diabetes mellitus. Urology. 2003;61(3):523-7. (Pubitemid 36297072)
29. Daudon M, Lacour B, Jungers P. High prevalence of uric acid calculi in diabetic stone formers. Nephrol Dial Transplant. 2005; 20(2):468-9. (Pubitemid 40276917)
30. Hershfield MS, et al. Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acidasan antioxidant in vivo. Proc Natl Acad Sci USA. 2010;107(32): 14351-6.
31. Pession A, Melchionda F, Castellini C. Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase). Biologics. 2008;2(1):129-41.
32. LaRosa C, et al. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol. 2007;22(1):132-5. (Pubitemid 46138373)
33. Fellstrom B, et al. The influence of a high dietary intake of purinerich animal protein on urinary urate excretion and supersaturation in renal stone disease. Clin Sci (Lond). 1983;64(4):399-405. (Pubitemid 13138622)
34. Kamel KS, et al. Recurrent uric acid stones. QJM. 2005;98 (1):57-68.
35. Steele TH, Boner G. Origins of the uricosuric response. J Clin Invest. 1973;52(6):1368-75.
36. Enomoto A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417(6887): 447-52. (Pubitemid 34563537)
37. Lipkowitz MS, et al. Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. J Clin Invest. 2001;107(9):1103-15. (Pubitemid 32422907)
38. Leal-Pinto E, et al. Functional analysis and molecular model of the human urate transporter/channel, hUAT. Am J Physiol Renal Physiol. 2002;283(1):F150-63. (Pubitemid 34680482)
39. Sorensen CM, Chandhoke PS. Hyperuricosuric calcium nephro-lithiasis. Endocrinol Metab Clin North Am. 2002;31(4):915-25.
40. Robertson WG. Renal stones in the tropics. Semin Nephrol. 2003; 23(1):77-87. (Pubitemid 36164471)
41. Pak CY, et al. Physicochemical metabolic characteristics for calcium oxalate stone formation in patients with gouty diathesis. J Urol. 2005;173(5):1606-9. (Pubitemid 40524784)
42. Pak CY, et al. Biochemical distinction between hyperuricosuric calcium urolithiasis and gouty diathesis. Urology. 2002;60(5): 789-94. (Pubitemid 35303376)
43. Pak CY, et al. Biochemical profile of idiopathic uric acid nephrolithiasis. Kidney Int. 2001;60(2):757-61. (Pubitemid 32680896)
44. Sakhaee K, et al. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int. 2002;62(3):971-9. (Pubitemid 35316727)
45. Sakhaee K, et al. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int. 1983;24(3):348-52. (Pubitemid 13023903)
46. Jones HB. On the variations of the acidity of the urine in the state of health. Philos Trans R Soc. 1845;135-8.
47. Mills JN, Stanbury SW. Intrinsic diurnal rhythm in urinary electrolyte output. J Physiol. 1951;115(1):18p-9p.
48. Moore-Ede MC, Herd JA. Renal electrolyte circadian rhythms: independence from feeding and activity patterns. Am J Physiol. 1977;232(2):F128-35. (Pubitemid 8067421)
49. Stanbury SW, Thomson AE. Diurnal variation in electrolyte excretion. Clin Sci (Lond). 1951;10(3):267-93.
50. Murayama T, et al. Role of the diurnal variation of urinary pH and urinary calcium in urolithiasis: a study in outpatients. Int J Urol. 2001;8(10):525-31. (discussion 532). (Pubitemid 32995987)
51. Cameron MA et al. Diurnal variation in urinary acidification parameters in normal subjects and uric acid stone formers. 2011: Manuscript in preparation.
52. Cameron MA, et al. Circadian variation in urine pH and uric acid nephrolithiasis risk. Nephrol Dial Transplant. 2007;22(8):2375-8. (Pubitemid 47244722)
53. Hamm LL, Simon EE. Roles and mechanisms of urinary buffer excretion. Am J Physiol. 1987; 253(4 Pt 2):F595-605.
54. Kamel KS, Cheema-Dhadli S, Halperin ML. Studies on the pathophysiology of the low urine pH in patients with uric acid stones. Kidney Int. 2002;61(3):988-94. (Pubitemid 34175467)
55. Cameron MA, et al. Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc Nephrol. 2006; 17(5):1422-8. (Pubitemid 43673423)
56. Maalouf NM, et al. Metabolic basis for low urine pH in type 2 diabetes. Clin J Am Soc Nephrol. 2010;5(7):1277-81.
57. Ekaratanawong S, et al. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J Pharmacol Sci. 2004;94(3):297-304. (Pubitemid 38470739)
58. Lieske JC, et al. Diabetes mellitus and the risk of urinary tract stones: a population-based case-control study. Am J Kidney Dis. 2006;48(6):897-904. (Pubitemid 44895375)
59. Abate N, et al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004;65(2):386-92. (Pubitemid 38130632)
60. Bobulescu IA, et al. Effect of renal lipid accumulation on proximal tubule Na +/H + exchange and ammonium secretion. Am J Physiol Renal Physiol. 2008;294(6):F1315-22.
61. Bobulescu IA, et al. Reduction of renal triglyceride accumulation: effects on proximal tubule Na+/H+ exchange and urinary acidification. Am J Physiol Renal Physiol. 2009;297(5):F1419-26.
62. Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int. 2008;73(4):489-96. (Pubitemid 351186291)
63. Calado J, et al. A novel heterozygous missense mutation in the UMOD gene responsible for Familial Juvenile Hyperuricemic Nephropathy. BMC Med Genet. 2005;6:5.
64. Bleyer AJ, et al. Renal manifestations of a mutation in the uro-modulin (Tamm Horsfall protein) gene. Am J Kidney Dis. 2003;42(2):E20-6.
65. Pak CY, et al. Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med. 2003;115(1): 26-32. (Pubitemid 36831118)
66. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844-54.
67. Diamond HS, et al. Hyperuricosuria and increased tubular secretion of urate in sickle cell anemia. Am J Med. 1975;59(6):796-802.
68. Reddy ST, et al. Effect of low-carbohydrate high-protein diets on acid-base balance, stone-forming propensity, and calcium metabolism. Am J Kidney Dis. 2002;40(2):265-74. (Pubitemid 34827643)
69. Pak CY, et al. Mechanism for calcium urolithiasis among patients with hyperuricosuria: supersaturation of urine with respect to monosodium urate. J Clin Invest. 1977;59(3):426-31. (Pubitemid 8061212)
70. Graff L. A handbook of routine urinalysis. Philadelphia: J.B. Lippincott Company; 1982.
71. Pais VM Jr, et al. Xanthine urolithiasis. Urology 2006; 67(5): 1084 e9-11.
72. Coe FL. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder. Ann Intern Med. 1977;87(4):404-10. (Pubitemid 8217077)
73. Ettinger B, et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986;315(22):1386-9. (Pubitemid 17055411)
74. Becker MA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23): 2450-61. (Pubitemid 41781828)
75. Pak CY, Sakhaee K, Fuller C. Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int. 1986;30(3): 422-8. (Pubitemid 16029514)
76. Moran ME, et al. Utility of oral dissolution therapy in the management of referred patients with secondarily treated uric acid stones. Urology. 2002;59(2):206-10. (Pubitemid 34134515)
77. Rodman JS. Prophylaxis of uric acid stones with alternate day doses of alkaline potassium salts. J Urol. 1991;145(1):97-9.
78. Preminger GM, Sakhaee K, Pak CY. Alkali action on the urinary crystallization of calcium salts: contrasting responses to sodium citrate and potassium citrate. J Urol. 1988;139(2):240-2.
79. Odvina CV. Comparative value of orange juice versus lemonade in reducing stone-forming risk. Clin J Am Soc Nephrol. 2006; 1(6):1269-74.